Aspirin, 110 years later

Although conceived at the end of the 19th century as a synthetic analgesic agent with improved gastric tolerability vs. naturally occurring salicylates, acetylsalicylic acid (marketed as aspirin in 1899) turned out to be an ideal antiplatelet agent about 90 years later, following the understanding o...

Full description

Saved in:
Bibliographic Details
Published inJournal of thrombosis and haemostasis Vol. 7; pp. 258 - 261
Main Authors PATRONO, C., ROCCA, B.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.07.2009
Subjects
Aspirin - history
Aspirin - therapeutic use
aspirin resistance
atherothrombosis
Drug Resistance
History, 20th Century
History, 21st Century
Humans
low‐dose aspirin
Platelet Aggregation Inhibitors
platelet COX‐1
primary prevention
Risk Assessment
Online AccessGet full text

Cover

More Information
Summary:Although conceived at the end of the 19th century as a synthetic analgesic agent with improved gastric tolerability vs. naturally occurring salicylates, acetylsalicylic acid (marketed as aspirin in 1899) turned out to be an ideal antiplatelet agent about 90 years later, following the understanding of its mechanism of action, the development of a mechanism‐based biomarker for dose‐finding studies, and the initiation of a series of appropriately sized, randomized clinical trials to test its efficacy and safety at low doses given once daily. At the turn of its 110th anniversary, aspirin continues to attract heated debates on a number of issues including (i) the optimal dose to maximize efficacy and minimize toxicity; (ii) the possibility that some patients may be ‘resistant’ to its antiplatelet effects; and (iii) the balance of benefits and risks in primary vs. secondary prevention.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1538-7933
1538-7836
1538-7836
DOI:10.1111/j.1538-7836.2009.03391.x